Participate in the Canadian Cancer Survivor Network Survey on trabectedin (Yondelis)!

The purpose of this survey is to provide the Canadian Cancer Survivor Network (CCSN) with insights and perspectives about the use of trabectedin (Yondelis) for the treatment of patients with metastatic liposarcoma or leiomyosarcoma after failure of prior anthracycline and ifosfamide chemotherapy.

This survey will be open until noon on January 12, 2016, 5 pm, to enable us to prepare our patient evidence submission to the pan-Canadian Oncology Drug Review (pCODR) on January 13, 2016.

You can access the survey at

Thank you for your participation!